Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression

Recently, the immune checkpoint inhibitor (ICI) pembrolizumab was demonstrated to be superior to platinum doublet chemotherapy in the first-line setting in patients with tumor programmed death-ligand 1 (PD-L1) expression of at least 50%. However, because patients with epidermal growth factor recepto...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Transl Med
Glavni autori: Uenami, Takeshi, Ishijima, Mikako, Kanazu, Masaki, Kurebe, Hiroyuki, Edahiro, Ryuya, Nishida, Kohei, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2018
Teme:
Case Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6281532/
https://ncbi.nlm.nih.gov/pubmed/30596074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2018.10.24
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items